Roche, Lilly drugs chosen for Alzheimer's prevention trial

Wed Oct 10, 2012 9:49am EDT

Oct 10 (Reuters) - Roche Holding AG's experimental drug gantenerumab and Eli Lilly & Co's solanezumab have been chosen to be tested in a high-profile global Alzheimer's disease prevention trial, and a second Lilly medicine is being considered for potential inclusion in the study, Washington University said on Wednesday.

The St. Louis-based University said the trial, expected to begin in early 2013, will enroll 160 patients with inherited gene mutations that typically lead to Alzheimer's disease at a young age.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.